novo nordisk's wegovy reduces cardiovascular risk more than lilly's tirzepatide Linked To Lower Heart Risks Similar Drugs Study Shows A high dose of Wegovy

Existing Health Conditions Both medications not only aid in weight loss but also help manage Type 2 diabetes and may improve heart health

Advertisements reflect the first-month rate only and dont note that refill pricing increases after that, which could mislead prospective patients about ongoing costs

A comparative analysis found subcutaneous semaglutide achieved better HbA1c reduction than oral semaglutide, while both still provided meaningful clinical benefits [4]

An example to keep in mind One common pitfall: a small controlled trial may show a benefit at a dose much higher than what a retail product offers

**$25/month savings card effective January 5, 2026 for commercially insured patients with coverage

Most symptoms were mild to moderate and happened during dose increases